NYSE:MRKPharmaceuticals
Merck Reorganizes Human Health To Shape Life After Keytruda
Merck (NYSE:MRK) is restructuring its Human Health division into two units: Oncology and Specialty, Pharma & Infectious Diseases.
The company has announced new executive appointments to lead each unit as part of this reorganization.
The move is intended to sharpen focus on cancer care and the broader portfolio ahead of Keytruda patent expiration.
With a current share price of $123.82, Merck comes into this reorganization after a strong run, with the stock up 14.5% over the past 30 days and...